Cargando…
Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413039/ https://www.ncbi.nlm.nih.gov/pubmed/37577312 http://dx.doi.org/10.21037/tlcr-23-202 |
| _version_ | 1785087048121581568 |
|---|---|
| author | Stinchcombe, Thomas E. |
| author_facet | Stinchcombe, Thomas E. |
| author_sort | Stinchcombe, Thomas E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10413039 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104130392023-08-11 Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial Stinchcombe, Thomas E. Transl Lung Cancer Res Editorial Commentary AME Publishing Company 2023-05-23 2023-07-31 /pmc/articles/PMC10413039/ /pubmed/37577312 http://dx.doi.org/10.21037/tlcr-23-202 Text en 2023 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Stinchcombe, Thomas E. Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial |
| title | Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial |
| title_full | Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial |
| title_fullStr | Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial |
| title_full_unstemmed | Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial |
| title_short | Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial |
| title_sort | selpercatinib in patients with ret fusion positive non-small cell lung cancer: updated follow-up of the libretto-001 phase i/ii trial |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413039/ https://www.ncbi.nlm.nih.gov/pubmed/37577312 http://dx.doi.org/10.21037/tlcr-23-202 |
| work_keys_str_mv | AT stinchcombethomase selpercatinibinpatientswithretfusionpositivenonsmallcelllungcancerupdatedfollowupofthelibretto001phaseiiitrial |